Concurrent Investment Advisors LLC Acquires 439 Shares of Edwards Lifesciences Co. (NYSE:EW)

Concurrent Investment Advisors LLC increased its holdings in Edwards Lifesciences Co. (NYSE:EW) by 2.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,626 shares of the medical research company’s stock after acquiring an additional 439 shares during the quarter. Concurrent Investment Advisors LLC’s holdings in Edwards Lifesciences were worth $1,453,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Abacus Planning Group Inc. increased its stake in Edwards Lifesciences by 0.3% during the 4th quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company’s stock valued at $2,977,000 after purchasing an additional 140 shares in the last quarter. Private Advisor Group LLC increased its stake in Edwards Lifesciences by 79.4% during the 4th quarter. Private Advisor Group LLC now owns 21,326 shares of the medical research company’s stock valued at $1,579,000 after purchasing an additional 9,440 shares in the last quarter. Pegasus Asset Management Inc. increased its stake in Edwards Lifesciences by 0.4% during the 4th quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company’s stock valued at $3,156,000 after purchasing an additional 159 shares in the last quarter. Venturi Wealth Management LLC increased its stake in Edwards Lifesciences by 1,013.3% during the 4th quarter. Venturi Wealth Management LLC now owns 2,683 shares of the medical research company’s stock valued at $199,000 after purchasing an additional 2,442 shares in the last quarter. Finally, D.A. Davidson & CO. increased its stake in Edwards Lifesciences by 3.1% during the 4th quarter. D.A. Davidson & CO. now owns 10,033 shares of the medical research company’s stock valued at $743,000 after purchasing an additional 300 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.00. Following the sale, the chief financial officer now owns 30,561 shares in the company, valued at $2,315,301.36. This trade represents a 26.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now owns 23,189 shares in the company, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 26,489 shares of company stock worth $2,002,829 over the last quarter. Insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

EW has been the subject of a number of analyst reports. Barclays raised their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Morgan Stanley raised their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, February 12th. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their price target for the company from $82.00 to $90.00 in a report on Monday, December 16th. The Goldman Sachs Group raised their price target on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, December 5th. Finally, Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their price target for the company from $75.00 to $90.00 in a report on Thursday, January 30th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences presently has an average rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Price Performance

NYSE EW opened at $73.25 on Friday. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The stock has a market cap of $43.20 billion, a price-to-earnings ratio of 10.51, a PEG ratio of 4.82 and a beta of 1.10. The company’s 50 day moving average is $72.85 and its two-hundred day moving average is $70.00. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.